/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 billion, the company’s products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis. The leading biotechnology company is expected to announce its fiscal third-quarter earnings for 2024 before the market opens on Wednesday, Oct. 30.
Ahead of the event, analysts expect BIIB to report a profit of $3.78 per share on a diluted basis, down 13.3% from $4.36 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.